Norvasc®, a calcium channel blocker, with an established record of efficacy and
safety in the treatment of hypertension was challenged by agents in a new class of drugs
called ARBs. At the time their supporting data were limited and we tried to communicate
that in a compelling way. Our client did not produce it, but it remains one of our favorites.
safety in the treatment of hypertension was challenged by agents in a new class of drugs
called ARBs. At the time their supporting data were limited and we tried to communicate
that in a compelling way. Our client did not produce it, but it remains one of our favorites.
Developed at Warhaftig Associates, Inc. for Pfizer Inc.
The writer on this project was Jon Hughes.
